<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269057</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10</org_study_id>
    <nct_id>NCT04269057</nct_id>
  </id_info>
  <brief_title>Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI</brief_title>
  <official_title>Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in Patients With Heart Failure With Preserved Ejection Fraction Treated With ARNI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Underlying inflammation has been increasingly recognized in heart failure with a preserved
      ejection fraction(HFpEF). But there is no study reported the relationship between NLRP3
      inflammasome and HFpEF. In this study, investigators propose a scientific hypothesis that the
      expression of NLRP3 inflammasome is elevated in patients with HFpEF, and the level of TNFα,
      IL-1β and NLRP3 inflammasome is lower in patients treated with sacubitril/valsartan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will integrate data from two trials involving a total of 90 participants with heart
      failure. Depending on the using of ARNI, participants in HFpEF group will be divided into two
      groups. The diagnostic criteria for HFpEF is: (1) left ventricular ejection fraction ≥50%；
      (2）with the symptoms and/or signs of heart failure; (3) BNP≥35 pg/mL and/or NTproBNP≥125
      pg/mL; (4) at least one additional criterion: a.relevant structural heart disease(LVH and/or
      LAE); b.diastolic dysfunction. The primary outcome are the change from baseline in TNFα,
      IL-1β, NLRP3 inflammasome, and so on assessed at 12 weeks. The key secondary outcomes include
      changes in echocardiographic measures, quality of life, etc. And then compare the rate of
      above indicators of two trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in TNFα, IL-1β, NLRP3 inflammasome, and so on assessed at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measuring the level of TNFα, IL-1β, NLRP3 inflammasome, and so on from blood samples at 12 weeks, seperately by PCR and ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in echocardiographic measures and so on</measure>
    <time_frame>12 months</time_frame>
    <description>Observed the change of ejection fraction, left atrial volume index and so on measured by echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Kansas City Cardiomyopathy Questionnaire. The score ranges from 0 to 100. The higher score means the better health-related quality of life.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <description>heart failure patients with preserved ejection fraction who using ARNI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <description>heart failure patients with reduced ejection fraction who using ARNI</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      monocytes and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        heart failure patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  left ventricular ejection fraction ≥50%；

          -  with the symptoms and/or signs of heart failure；

          -  BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL；

          -  at least one additional criterion: relevant structural heart disease(LVH and/or LAE)
             or diastolic dysfunction.

        Exclusion Criteria:

          -  LVEF less than 45% at any time;

          -  severe infection;

          -  ACS;

          -  pregnancy;

          -  eGFR ＜30 mL/min/1.73 m2, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongying Zhang, doctor</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongying Zhang, doctor</last_name>
    <phone>+8613608398395</phone>
    <email>zdy.chris@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongying Zhang, doctor</last_name>
      <phone>+8613608398395</phone>
      <email>zdy.chris@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Dongying Zhang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>NLRP3 protein</keyword>
  <keyword>human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

